PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
38.68%
Cash & equivalents growing 38.68% while CRVO's declined -0.25%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
38.68%
Below half of CRVO's -0.25%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.26%
Below half of CRVO's -6.60%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
101.21%
Below half CRVO's -53.96%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
101.21%
Below half of CRVO's 62635.66%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
42.36%
Below half of CRVO's 467.14%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-44.89%
Above 1.5x CRVO's -1.33%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
146.14%
Less than half of CRVO's -8.39%. David Dodd sees fewer expansions in other current obligations.
112.59%
Less than half of CRVO's -7.23%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
112.59%
Above 1.5x CRVO's 24.12%. Michael Burry sees a potential leverage warning sign.
-89.62%
Similar yoy changes to CRVO's -98.62%. Walter Schloss sees parallel capital-raising strategies.
-9.70%
≥ 1.5x CRVO's -1.62%. David Dodd sees higher yoy retained profits than competitor.
98.99%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
100.73%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-358.06%
Below half CRVO's 202.70%. Michael Burry sees potential underperformance in building shareholder capital.
42.36%
Below half CRVO's 467.14%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-34.72%
1.1-1.25x CRVO's -30.50%. Bill Ackman questions if net debt is increasing faster than competitor.